Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides

Randy Carney, Sidhartha Hazari, Tatu Rojalin, Alisha Knudson, Tingjuan Gao, Yuchen Tang, Ruiwu Liu, Tapani Viitala, Marjo Yliperttula, Kit Lam

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

All cells expel a variety of nanosized extracellular vesicles (EVs), including exosomes, with composition reflecting the cells' biological state. Cancer pathology is dramatically mediated by EV trafficking via key proteins, lipids, metabolites, and microRNAs. Recent proteomics evidence suggests that tumor-associated exosomes exhibit distinct expression of certain membrane proteins, rendering those proteins as attractive targets for diagnostic or therapeutic application, yet it is not currently feasible to distinguish circulating EVs in complex biofluids according to their tissue of origin or state of disease. Here, peptide binding to tumor-associated EVs via overexpressed membrane protein is demonstrated. It is found that SKOV-3 ovarian tumor cells and their released EVs express α 3 β 1 integrin, which can be targeted by the in-house cyclic nonapeptide, LXY30. After measuring bulk SKOV-3 EV association with LXY30 by flow cytometry, Raman spectral analysis of laser-trapped single exosomes with LXY30-dialkyne conjugate enables the differentiation of cancer-associated exosomes from noncancer exosomes. Furthermore, the foundation for a highly specific detection platform for tumor-EVs in solution with biosensor surface-immobilized LXY30 is introduced. LXY30 not only exhibits high specificity and affinity to α 3 β 1 integrin-expressing EVs, but also reduces EV uptake into SKOV-3 parent cells, demonstrating the possibility for therapeutic application.

Original languageEnglish (US)
Article number1600038
JournalAdvanced Biosystems
Volume1
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Exosomes
Integrins
Peptides
Tumors
Proteins
Neoplasms
Membrane Proteins
Membranes
Flow cytometry
Pathology
Metabolites
MicroRNAs
Biosensors
Spectrum analysis
Lipids
Cells
Association reactions
Tissue
Extracellular Vesicles
Lasers

Keywords

  • biosensors
  • cancer
  • diagnostics
  • exosomes
  • optical tweezers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biomaterials
  • Biomedical Engineering

Cite this

Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides. / Carney, Randy; Hazari, Sidhartha; Rojalin, Tatu; Knudson, Alisha; Gao, Tingjuan; Tang, Yuchen; Liu, Ruiwu; Viitala, Tapani; Yliperttula, Marjo; Lam, Kit.

In: Advanced Biosystems, Vol. 1, No. 5, 1600038, 01.05.2017.

Research output: Contribution to journalArticle

Carney, R, Hazari, S, Rojalin, T, Knudson, A, Gao, T, Tang, Y, Liu, R, Viitala, T, Yliperttula, M & Lam, K 2017, 'Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides', Advanced Biosystems, vol. 1, no. 5, 1600038. https://doi.org/10.1002/adbi.201600038
Carney, Randy ; Hazari, Sidhartha ; Rojalin, Tatu ; Knudson, Alisha ; Gao, Tingjuan ; Tang, Yuchen ; Liu, Ruiwu ; Viitala, Tapani ; Yliperttula, Marjo ; Lam, Kit. / Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides. In: Advanced Biosystems. 2017 ; Vol. 1, No. 5.
@article{911904f98d0f4152b62e0052f2b612ad,
title = "Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides",
abstract = "All cells expel a variety of nanosized extracellular vesicles (EVs), including exosomes, with composition reflecting the cells' biological state. Cancer pathology is dramatically mediated by EV trafficking via key proteins, lipids, metabolites, and microRNAs. Recent proteomics evidence suggests that tumor-associated exosomes exhibit distinct expression of certain membrane proteins, rendering those proteins as attractive targets for diagnostic or therapeutic application, yet it is not currently feasible to distinguish circulating EVs in complex biofluids according to their tissue of origin or state of disease. Here, peptide binding to tumor-associated EVs via overexpressed membrane protein is demonstrated. It is found that SKOV-3 ovarian tumor cells and their released EVs express α 3 β 1 integrin, which can be targeted by the in-house cyclic nonapeptide, LXY30. After measuring bulk SKOV-3 EV association with LXY30 by flow cytometry, Raman spectral analysis of laser-trapped single exosomes with LXY30-dialkyne conjugate enables the differentiation of cancer-associated exosomes from noncancer exosomes. Furthermore, the foundation for a highly specific detection platform for tumor-EVs in solution with biosensor surface-immobilized LXY30 is introduced. LXY30 not only exhibits high specificity and affinity to α 3 β 1 integrin-expressing EVs, but also reduces EV uptake into SKOV-3 parent cells, demonstrating the possibility for therapeutic application.",
keywords = "biosensors, cancer, diagnostics, exosomes, optical tweezers",
author = "Randy Carney and Sidhartha Hazari and Tatu Rojalin and Alisha Knudson and Tingjuan Gao and Yuchen Tang and Ruiwu Liu and Tapani Viitala and Marjo Yliperttula and Kit Lam",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/adbi.201600038",
language = "English (US)",
volume = "1",
journal = "Advanced Biosystems",
issn = "2366-7478",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides

AU - Carney, Randy

AU - Hazari, Sidhartha

AU - Rojalin, Tatu

AU - Knudson, Alisha

AU - Gao, Tingjuan

AU - Tang, Yuchen

AU - Liu, Ruiwu

AU - Viitala, Tapani

AU - Yliperttula, Marjo

AU - Lam, Kit

PY - 2017/5/1

Y1 - 2017/5/1

N2 - All cells expel a variety of nanosized extracellular vesicles (EVs), including exosomes, with composition reflecting the cells' biological state. Cancer pathology is dramatically mediated by EV trafficking via key proteins, lipids, metabolites, and microRNAs. Recent proteomics evidence suggests that tumor-associated exosomes exhibit distinct expression of certain membrane proteins, rendering those proteins as attractive targets for diagnostic or therapeutic application, yet it is not currently feasible to distinguish circulating EVs in complex biofluids according to their tissue of origin or state of disease. Here, peptide binding to tumor-associated EVs via overexpressed membrane protein is demonstrated. It is found that SKOV-3 ovarian tumor cells and their released EVs express α 3 β 1 integrin, which can be targeted by the in-house cyclic nonapeptide, LXY30. After measuring bulk SKOV-3 EV association with LXY30 by flow cytometry, Raman spectral analysis of laser-trapped single exosomes with LXY30-dialkyne conjugate enables the differentiation of cancer-associated exosomes from noncancer exosomes. Furthermore, the foundation for a highly specific detection platform for tumor-EVs in solution with biosensor surface-immobilized LXY30 is introduced. LXY30 not only exhibits high specificity and affinity to α 3 β 1 integrin-expressing EVs, but also reduces EV uptake into SKOV-3 parent cells, demonstrating the possibility for therapeutic application.

AB - All cells expel a variety of nanosized extracellular vesicles (EVs), including exosomes, with composition reflecting the cells' biological state. Cancer pathology is dramatically mediated by EV trafficking via key proteins, lipids, metabolites, and microRNAs. Recent proteomics evidence suggests that tumor-associated exosomes exhibit distinct expression of certain membrane proteins, rendering those proteins as attractive targets for diagnostic or therapeutic application, yet it is not currently feasible to distinguish circulating EVs in complex biofluids according to their tissue of origin or state of disease. Here, peptide binding to tumor-associated EVs via overexpressed membrane protein is demonstrated. It is found that SKOV-3 ovarian tumor cells and their released EVs express α 3 β 1 integrin, which can be targeted by the in-house cyclic nonapeptide, LXY30. After measuring bulk SKOV-3 EV association with LXY30 by flow cytometry, Raman spectral analysis of laser-trapped single exosomes with LXY30-dialkyne conjugate enables the differentiation of cancer-associated exosomes from noncancer exosomes. Furthermore, the foundation for a highly specific detection platform for tumor-EVs in solution with biosensor surface-immobilized LXY30 is introduced. LXY30 not only exhibits high specificity and affinity to α 3 β 1 integrin-expressing EVs, but also reduces EV uptake into SKOV-3 parent cells, demonstrating the possibility for therapeutic application.

KW - biosensors

KW - cancer

KW - diagnostics

KW - exosomes

KW - optical tweezers

UR - http://www.scopus.com/inward/record.url?scp=85054719617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054719617&partnerID=8YFLogxK

U2 - 10.1002/adbi.201600038

DO - 10.1002/adbi.201600038

M3 - Article

AN - SCOPUS:85054719617

VL - 1

JO - Advanced Biosystems

JF - Advanced Biosystems

SN - 2366-7478

IS - 5

M1 - 1600038

ER -